Vivarelli M , et al.. Minimal change disease. Clin Am J Soc Nephrol 2017; 12:332−345. doi: 10.2215/CJN.05000516

• PubMed
Vivarelli M , . Minimal change disease. Clin Am J Soc Nephrol 2017; 12:332−345. doi: 10.2215/CJN.05000516 )| false
• Search Google Scholar
• Export Citation

Shalhoub RJ . Pathogenesis of lipoid nephrosis: A disorder of T-cell function. Lancet 1974; 2:556−560. doi: 10.1016/s0140-6736(74)91880-7

• PubMed
Shalhoub RJ . Pathogenesis of lipoid nephrosis: A disorder of T-cell function. Lancet 1974; 2:556−560. doi: 10.1016/s0140-6736(74)91880-7 )| false
• Search Google Scholar
• Export Citation

Maas RJ , et al.. Permeability factors in idiopathic nephrotic syndrome: Historical perspectives and lessons for the future. Nephrol Dial Transplant 2014; 29:2207−2216. doi: 10.1093/ndt/gfu355

• PubMed
Maas RJ , . Permeability factors in idiopathic nephrotic syndrome: Historical perspectives and lessons for the future. Nephrol Dial Transplant 2014; 29:2207−2216. doi: 10.1093/ndt/gfu355 )| false
• Search Google Scholar
• Export Citation

Hogan J , Radhakrishnan J . The treatment of minimal change disease in adults. J Am Soc Nephrol 2013; 24:702−711. doi: 10.1681/ASN.2012070734

• PubMed
Hogan J , Radhakrishnan J . The treatment of minimal change disease in adults. J Am Soc Nephrol 2013; 24:702−711. doi: 10.1681/ASN.2012070734 )| false
• Search Google Scholar
• Export Citation

Tarshish P , et al.. Prognostic significance of the early course of minimal change nephrotic syndrome: Report of the International Study of Kidney Disease in Children. J Am Soc Nephrol 1997; 8:769−776. https://jasn.asnjournals.org/content/jnephrol/8/5/769.full.pdf?with-ds=yes

• PubMed
Tarshish P , . Prognostic significance of the early course of minimal change nephrotic syndrome: Report of the International Study of Kidney Disease in Children. J Am Soc Nephrol 1997; 8:769−776. https://jasn.asnjournals.org/content/jnephrol/8/5/769.full.pdf?with-ds=yes )| false
• Search Google Scholar
• Export Citation

Black DA , et al.. Controlled trial of prednisone in adult patients with the nephrotic syndrome. Br Med J 1970; 3:421−426. doi: 10.1136/bmj.3.5720.421

• PubMed
Black DA , . Controlled trial of prednisone in adult patients with the nephrotic syndrome. Br Med J 1970; 3:421−426. doi: 10.1136/bmj.3.5720.421 )| false
• Search Google Scholar
• Export Citation

Nakayama M , et al.. Steroid responsiveness and frequency of relapse in adult-onset minimal change nephrotic syndrome. Am J Kidney Dis 2002; 39:503−512. doi: 10.1053/ajkd.2002.31400

• PubMed
Nakayama M , . Steroid responsiveness and frequency of relapse in adult-onset minimal change nephrotic syndrome. Am J Kidney Dis 2002; 39:503−512. doi: 10.1053/ajkd.2002.31400 )| false
• Search Google Scholar
• Export Citation

Waldman M , et al.. Adult minimal-change disease: Clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol 2007; 2:445−453. doi: 10.2215/CJN.03531006

• PubMed
Waldman M , . Adult minimal-change disease: Clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol 2007; 2:445−453. doi: 10.2215/CJN.03531006 )| false
• Search Google Scholar
• Export Citation

Tse K-C , et al.. Idiopathic minimal change nephrotic syndrome in older adults: Steroid responsiveness and pattern of relapses. Nephrol Dial Transplant 2003; 18:1316−1320. doi: 10.1093/ndt/gfg134

• PubMed
Tse K-C , . Idiopathic minimal change nephrotic syndrome in older adults: Steroid responsiveness and pattern of relapses. Nephrol Dial Transplant 2003; 18:1316−1320. doi: 10.1093/ndt/gfg134 )| false
• Search Google Scholar
• Export Citation

Chapter 5: Minimal-change disease in adults. Kidney Int Suppl 2012; 2:177−180. doi:10.1038/kisup.2012.1

• PubMed
Chapter 5: Minimal-change disease in adults. Kidney Int Suppl 2012; 2:177−180. doi:10.1038/kisup.2012.1 )| false
• Search Google Scholar
• Export Citation

Boumpas DT , et al.. Glucocorticoid therapy for immune-mediated diseases: Basic and clinical correlates. Ann Intern Med 1993; 119:1198−1208. doi: 10.7326/0003-4819-119-12-199312150-00007

• PubMed
Boumpas DT , . Glucocorticoid therapy for immune-mediated diseases: Basic and clinical correlates. Ann Intern Med 1993; 119:1198−1208. doi: 10.7326/0003-4819-119-12-199312150-00007 )| false
• Search Google Scholar
• Export Citation

Huscher D , et al.. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis 2009; 68:1119−1124. doi: 10.1136/ard.2008.092163

• PubMed
Huscher D , . Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis 2009; 68:1119−1124. doi: 10.1136/ard.2008.092163 )| false
• Search Google Scholar
• Export Citation

Whitworth JA . Mechanisms of glucocorticoid-induced hypertension. Kidney Int 1987; 31:1213−1224. doi: 10.1038/ki.1987.131

• PubMed
Whitworth JA . Mechanisms of glucocorticoid-induced hypertension. Kidney Int 1987; 31:1213−1224. doi: 10.1038/ki.1987.131 )| false
• Search Google Scholar
• Export Citation

Gabriel SE , et al.. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991; 115:787−796. doi: 10.7326/0003-4819-115-10-787

• PubMed
Gabriel SE , . Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991; 115:787−796. doi: 10.7326/0003-4819-115-10-787 )| false
• Search Google Scholar
• Export Citation

van Staa TP , et al.. The epidemiology of corticosteroid-induced osteoporosis: A meta-analysis. Osteoporosis Int 2002; 13:777−787. doi: 10.1007/s001980200108

• PubMed
van Staa TP , . The epidemiology of corticosteroid-induced osteoporosis: A meta-analysis. Osteoporosis Int 2002; 13:777−787. doi: 10.1007/s001980200108 )| false
• Search Google Scholar
• Export Citation

Gurwitz JH , et al.. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med 1994; 154:97−101. doi: 10.1001/archinte.1994.00420010131015

• PubMed
Gurwitz JH , . Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med 1994; 154:97−101. doi: 10.1001/archinte.1994.00420010131015 )| false
• Search Google Scholar
• Export Citation

Dixon WG , et al.. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: A nested case-control analysis. Ann Rheum Dis 2012; 71:1128−1133. doi: 10.1136/annrheumdis-2011-200702

• PubMed
Dixon WG , . Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: A nested case-control analysis. Ann Rheum Dis 2012; 71:1128−1133. doi: 10.1136/annrheumdis-2011-200702 )| false
• Search Google Scholar
• Export Citation

Pepper RJ , et al.. A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford) 2019; 58:260−268. doi: 10.1093/rheumatology/key288

• PubMed
Pepper RJ , . A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford) 2019; 58:260−268. doi: 10.1093/rheumatology/key288 )| false
• Search Google Scholar
• Export Citation

Fervenza FC , et al.. Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med 2019; 381:36−46. doi: 10.1056/NEJMoa1814427

• PubMed
Fervenza FC , . Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med 2019; 381:36−46. doi: 10.1056/NEJMoa1814427 )| false
• Search Google Scholar
• Export Citation

Medjeral-Thomas NR , et al.. Randomized, controlled trial of tacrolimus and prednisolone monotherapy for adults with de novo minimal change disease: A multicenter, randomized, controlled trial. Clin J Am Soc Nephrol 2020; 15:209−218. doi: 10.2215/CJN.06180519

• PubMed
Medjeral-Thomas NR , . Randomized, controlled trial of tacrolimus and prednisolone monotherapy for adults with de novo minimal change disease: A multicenter, randomized, controlled trial. Clin J Am Soc Nephrol 2020; 15:209−218. doi: 10.2215/CJN.06180519 )| false
• Search Google Scholar
• Export Citation

Chin HJ , et al.. Comparison of the efficacy and safety of tacrolimus and low-dose corticosteroid with high-dose corticosteroid for minimal change nephrotic syndrome in adults. J Am Soc Nephrol 2021; 32:199−210. doi: 10.1681/ASN.2019050546

• PubMed
Chin HJ , . Comparison of the efficacy and safety of tacrolimus and low-dose corticosteroid with high-dose corticosteroid for minimal change nephrotic syndrome in adults. J Am Soc Nephrol 2021; 32:199−210. doi: 10.1681/ASN.2019050546 )| false
• Search Google Scholar
• Export Citation

Ainley L , et al.. Treatment of concurrent minimal change disease and Epstein Barr virus-driven post-transplant lymphoproliferative disorder with rituximab following hematopoietic stem cell transplantation. Kidney Int Rep 2021; 6:224−227. doi: 10.1016/j.ekir.2020.10.012

• PubMed
Ainley L , . Treatment of concurrent minimal change disease and Epstein Barr virus-driven post-transplant lymphoproliferative disorder with rituximab following hematopoietic stem cell transplantation. Kidney Int Rep 2021; 6:224−227. doi: 10.1016/j.ekir.2020.10.012 )| false
• Search Google Scholar
• Export Citation

Fenoglio R , et al.. Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome. Oncotarget 2018; 9:28799−28804. doi: 10.18632/oncotarget.25612.

• PubMed
Fenoglio R , . Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome. Oncotarget 2018; 9:28799−28804. doi: 10.18632/oncotarget.25612.)| false
• Search Google Scholar
• Export Citation

Kim YC , et al.. Complete remission induced by tacrolimus and low-dose prednisolone in adult minimal change nephrotic syndrome: A pilot study. Kidney Res Clin Pract 2012; 31:112−117. doi: 10.1016/j.krcp.2012.04.321

• PubMed
Kim YC , . Complete remission induced by tacrolimus and low-dose prednisolone in adult minimal change nephrotic syndrome: A pilot study. Kidney Res Clin Pract 2012; 31:112−117. doi: 10.1016/j.krcp.2012.04.321 )| false
• Search Google Scholar
• Export Citation

Li X , et al.. Tacrolimus monotherapy after intravenous methylprednisolone in adults with minimal change nephrotic syndrome. J Am Soc Nephrol 2017; 28:1286−1295. doi: 10.1681/ASN.2016030342

• PubMed
Li X , . Tacrolimus monotherapy after intravenous methylprednisolone in adults with minimal change nephrotic syndrome. J Am Soc Nephrol 2017; 28:1286−1295. doi: 10.1681/ASN.2016030342 )| false
• Search Google Scholar
• Export Citation